BCL2 and diffuse large B-cell lymphoma: Further, in a phase I, open-label, dose-escalation study, combination of fimepinostat (CUDC-907), a PI3K and HDAC inhibitor, with venetoclax and/or rituximab has been tested for antileukemic activity and tolerability in patients with relapsed and/or refractory DLBCL or high-grade B-cell lymphoma with or without MYC and BCL-2 alterations (NCT01742988).